Indication and Implementation of Lipidapheresis, Rheopheresis, or Immunoadsorption (Lessons learnt from Germany's largest apheresis center)
Atherosclerosis Supplements, ISSN: 1567-5688, Vol: 10, Issue: 5, Page: 137-141
2009
- 14Citations
- 41Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Efficient modes of extracorporeal blood purification are available today for apheresis treatment of progessive atherosclerosis, autoimmune disease, or for improving hemorheology. Advanced technology and sophisticated care render apheresis treatment selective, safe and tolerable. Our task is to constantly update indications for apheresis based on best evidence available and good clinical practice, as well as, to determine how apheresis therapy can be made available to those in need or with otherwise refractory disease.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S156756880971829X; http://dx.doi.org/10.1016/s1567-5688(09)71829-x; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=72749083644&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/20129393; http://linkinghub.elsevier.com/retrieve/pii/S156756880971829X; http://api.elsevier.com/content/article/PII:S156756880971829X?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S156756880971829X?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S156756880971829X; http://dx.doi.org/10.1016/s1567-5688%2809%2971829-x; https://dx.doi.org/10.1016/s1567-5688%2809%2971829-x
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know